Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free CREO Stock Alerts

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 13.50 +0.25 (+1.89%)
As of 03:47 AM Eastern
Compare

CREO vs. MXCT, EKF, IUG, NCYT, and IHC

Should you buy Creo Medical Group stock or one of its competitors? MarketBeat compares Creo Medical Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creo Medical Group include MaxCyte (MXCT), EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), and Inspiration Healthcare Group (IHC). These companies are all part of the "medical devices" industry.

How does Creo Medical Group compare to MaxCyte?

MaxCyte (LON:MXCT) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Creo Medical Group has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.03-£45.08M-£40.00N/A
Creo Medical Group£6M10.93-£25.04M£1.0013.50

Creo Medical Group has a net margin of 88.33% compared to MaxCyte's net margin of -119.69%. Creo Medical Group's return on equity of 9.56% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-119.69% -11.59% -11.07%
Creo Medical Group 88.33%9.56%-20.09%

24.0% of MaxCyte shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 1.9% of MaxCyte shares are owned by insiders. Comparatively, 6.9% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MaxCyte has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6212822, suggesting that its share price is 62% more volatile than the broader market.

In the previous week, Creo Medical Group had 1 more articles in the media than MaxCyte. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
MaxCyte Neutral
Creo Medical Group Neutral

Summary

Creo Medical Group beats MaxCyte on 10 of the 12 factors compared between the two stocks.

How does Creo Medical Group compare to EKF Diagnostics?

Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Creo Medical Group and Creo Medical Group both had 1 articles in the media. Creo Medical Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
EKF Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 22.0% of EKF Diagnostics shares are owned by institutional investors. 6.9% of Creo Medical Group shares are owned by company insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.93-£25.04M£1.0013.50
EKF Diagnostics£51.56M2.12£4.68M£0.4753.94

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
EKF Diagnostics 4.12%3.01%5.27%

Creo Medical Group has a beta of 1.6212822, meaning that its share price is 62% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.513, meaning that its share price is 49% less volatile than the broader market.

Creo Medical Group presently has a consensus target price of GBX 40, suggesting a potential upside of 196.30%. EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 38.07%. Given Creo Medical Group's higher possible upside, equities analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Creo Medical Group and EKF Diagnostics tied by winning 7 of the 14 factors compared between the two stocks.

How does Creo Medical Group compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Intelligent Ultrasound Group has higher revenue and earnings than Creo Medical Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
Creo Medical Group£6M10.93-£25.04M£1.0013.50

Creo Medical Group has a net margin of 88.33% compared to Intelligent Ultrasound Group's net margin of -23.11%. Creo Medical Group's return on equity of 9.56% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
Creo Medical Group 88.33%9.56%-20.09%

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by company insiders. Comparatively, 6.9% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Creo Medical Group had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for Intelligent Ultrasound Group. Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
Creo Medical Group Neutral

Intelligent Ultrasound Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6212822, suggesting that its share price is 62% more volatile than the broader market.

Summary

Creo Medical Group beats Intelligent Ultrasound Group on 6 of the 11 factors compared between the two stocks.

How does Creo Medical Group compare to Novacyt?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Creo Medical Group and Creo Medical Group both had 1 articles in the media. Novacyt's average media sentiment score of 1.42 beat Creo Medical Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Novacyt
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.93-£25.04M£1.0013.50
Novacyt£20.03M1.32-£36.80M-£32.00N/A

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -103.08%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Novacyt -103.08%-96.44%-27.98%

Creo Medical Group has a beta of 1.6212822, indicating that its share price is 62% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 6.9% of Creo Medical Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Creo Medical Group beats Novacyt on 10 of the 12 factors compared between the two stocks.

How does Creo Medical Group compare to Inspiration Healthcare Group?

Creo Medical Group (LON:CREO) and Inspiration Healthcare Group (LON:IHC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 7.4% of Inspiration Healthcare Group shares are held by institutional investors. 6.9% of Creo Medical Group shares are held by insiders. Comparatively, 6.1% of Inspiration Healthcare Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Creo Medical Group had 1 more articles in the media than Inspiration Healthcare Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for Inspiration Healthcare Group. Inspiration Healthcare Group's average media sentiment score of 1.61 beat Creo Medical Group's score of 0.00 indicating that Inspiration Healthcare Group is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Neutral
Inspiration Healthcare Group Very Positive

Inspiration Healthcare Group has higher revenue and earnings than Creo Medical Group. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.93-£25.04M£1.0013.50
Inspiration Healthcare Group£47.55M0.35-£12.20M-£1.16N/A

Creo Medical Group has a net margin of 88.33% compared to Inspiration Healthcare Group's net margin of -2.19%. Creo Medical Group's return on equity of 9.56% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Inspiration Healthcare Group -2.19%-6.49%-3.47%

Creo Medical Group has a beta of 1.6212822, meaning that its share price is 62% more volatile than the broader market. Comparatively, Inspiration Healthcare Group has a beta of 0.872, meaning that its share price is 13% less volatile than the broader market.

Summary

Creo Medical Group beats Inspiration Healthcare Group on 9 of the 13 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

Export
MetricCreo Medical GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£65.58M£2.28B£7.04B£2.85B
Dividend YieldN/A2.59%2.65%6.15%
P/E Ratio13.5015.0127.65367.96
Price / Sales10.93129.53490.1884,359.52
Price / Cash2.4315.9951.7427.89
Price / Book1.034.7410.057.03
Net Income-£25.04M£144.75M£3.60B£5.89B
7 Day Performance-1.82%0.69%0.67%0.60%
1 Month Performance-7.46%3.16%-3.28%0.95%
1 Year Performance3.45%-2.11%24.49%68.91%

Creo Medical Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 13.50
+1.9%		GBX 40
+196.3%		+1.4%£65.58M£6M13.50279
MXCT
MaxCyte
N/AGBX 1.12
-1.8%		N/A-53.3%£170.11M£32.29MN/A80
EKF
EKF Diagnostics
1.6706 of 5 stars		GBX 25.70
-1.2%		GBX 35
+36.2%		-11.6%£110.58M£51.56M54.68356
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 38
-4.0%		N/A-9.7%£27.53M£20.03MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CREO) was last updated on 7/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel